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Abstract: The house dust mite is a major cause of respiratory allergy worldwide. The manage-
ment of mite allergy is based on avoidance measures, drug treatment, and allergen immuno-
therapy, but only allergen immunotherapy is able to modify the natural history of the disease. 
Injectable subcutaneous immunotherapy was introduced a century ago, while sublingual 
immunotherapy was proposed in the 1980s and emerged in the ensuing years as an effective and 
safe option to subcutaneous immunotherapy. However, the quality of the extracts to be used in 
allergen immunotherapy is crucial for the success of treatment. The mite extract for sublingual 
immunotherapy known as Staloral 300 was developed to offer optimal characteristics concerning 
the mite culture medium, standardization, and allergen dose. Double-blind, placebo-controlled 
trials with Staloral 300 have provided a substantial part of the clinical evidence analyzed in a 
meta-analysis of the efficacy of allergen immunotherapy in mite-induced rhinitis and asthma. 
Safety and tolerability are very good, mild local reactions in the mouth being the most com-
mon side effect. This makes it feasible to carry out sublingual immunotherapy for the 3–5-year 
duration needed to achieve long-lasting tolerance to the specific allergen. The performance of 
Staloral 300 may provide optimal conditions for an effective and safe sublingual immunotherapy 
in patients with mite-induced respiratory allergy.
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Introduction
The house dust mite is a major cause of respiratory allergy worldwide.1–3 Mites are taxo-
nomically classified into more than 50,000 species, but those belonging to the subfamily 
of Pyroglyphidae, and particularly the species Dermatophagoides pteronyssinus and Der-
matophagoides farinae, are particularly involved in allergic diseases.4 D. pteronyssinus 
and D. farinae generally coexist, humidity being the main factor favoring the former.2 A 
large number of allergens, comprising a number of different groups, has been identified 
in Dermatophagoides spp, ie, groups 1–11, 13 and 14, and 15–18, are present in both 
species, while group 20 is specific for D. pteronyssinus.5,6 In particular, group 1 and 
2 include the major allergens Der p 1/Der f 1 and Der p 2/Der f 2, respectively, that are 
recognized by IgE antibodies in more than 70% of mite-allergic patients.7 Both Der p 
1/Der f 1 and Der p 2/Der f 2 are generally found within mite fecal pellets, and reach 
high concentrations in indoor environments.7,8 Other clinically important allergens 
comprise groups 5, 7, 8, and 10,9 the latter including tropomyosin, which accounts 
for cross-reactivity with crustaceans and molluscs and thus for allergic reactions to 
foods.10 Two studies have systematically examined the amount of IgE binding to the 
different dust mite allergens.11,12 Der p 1/Der f 1 are proteolytic enzymes with optimal 
characteristics to act as allergens,13 but also show biological activity favoring allergic 
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sensitization. In particular, Der p 1 affects tolerance through 
downregulation of indoleamine 2–3-dioxygenase expression in 
dendritic cells; stimulates the production of interleukin (IL)-4; 
decreases interferon-γ; degrades airway antiprotease-based 
lung defenses, leading to tissue damage; digests intercellular 
tight junction proteins, increasing the permeability of epithe-
lium; directly activates airway epithelial cells, promoting pro-
duction of proinflammatory cytokines, such as interleukin-6 
(IL-6), IL-8, and granulocyte-macrophage colony-stimulating 
factor; activates human myeloid and plasmacytoid dendritic 
cells to initiate Th2 cell responses; and directly elicits changes 
in airway smooth-muscle responsiveness.14–16 Moreover, the 
protease activity of Der p 1/Der f 1 favors their facilitated 
entry through the skin and capture by dendritic cells17 that 
activate an initially local Th2 but a later Th1 response, along 
with a systemic Th2 response inducing isotype switching 
to IgE synthesis and involvement of eosinophils.18 Of note, 
Dermatophagoides spp are the only source of allergens with 
a protease being the major specificity. The ongoing inflamma-
tory process is then sustained by Th2-related cytokines, such 
as tumor necrosis factor-α, IL-5, IL-13, IL-17, and IL-31, the 
latter being primarily expressed in skin-homing Th2 cells.19 
This, together with impaired function of filaggrin, which is a 
structural protein associated with filaments which are bound 
to keratin fibers in epidermal cells and ensures the barrier 
function to skin, is likely to account for the natural history of 
allergy to the house dust mite.20
The treatment strategies to counteract this series of 
events are drug therapy, and especially topical and inhaled 
corticosteroids (but cannot act once treatment is stopped),21 
allergen avoidance that is unable to reduce house dust mite 
concentration to less than the sensitization threshold level,22 
and allergen immunotherapy. Allergen immunotherapy was 
introduced 100 years ago and showed constant evolution, also 
based on the improvement of quality of allergen extracts.23 
Currently, there are two routes of administration of allergen 
extract, ie, subcutaneous immunotherapy and sublingual 
immunotherapy. This paper deals with the development of 
a pharmaceutical grade allergen extract of D. pteronyssinus 
and D. farinae, which represents a high-quality standardized 
product by which the performance of allergen immunotherapy 
can be improved.
Obtaining a high-quality mite 
allergen extract
The quality of an allergen extract is related to the adequacy of 
the original material and to standardization, enabling repro-
ducibility of allergenic potency in extracts from different 
batches. Concerning the original material, unlike pollens, 
mites cannot be derived from naturally occurring sources 
but require cultivation in the laboratory, where the culture 
medium used is of pivotal importance.
Culture medium
The house dust mite feeds on human skin scales (giving 
the name Dermatophagoides after the Latin meaning “eat-
ing the skin”) present in beds, upholstery, and carpets.24 
However, material of human or animal origin must not be 
used for safety reasons in the culture medium used in the 
laboratory. Also, an optimal culture medium must allow 
growth of house dust mite expressing all major allergens and 
exclude any nonmite allergens. In the Stallergenes laboratory 
(Antony, France) an optimal culture medium (Stalmite APF 
[animal protein-free]) resembling the composition of the 
human stratum corneum and based on wheat germ, yeast, 
and amino acids in defined proportions of 42%, 42%, and 
15% w/w, respectively, was developed. A proteomic analysis 
showed that D. pteronyssinus extracts obtained in such a state 
did not contain allergens developing from culture medium 
components and that the major group 1 and 2 allergens were 
demonstrated to be present as well as the allergens from 
groups 7, 10, 13, and 20. Groups 13 and 20 appear to be of 
little importance.25
Standardization
The process of standardization is based on: collection 
and selection of raw material from dust mites cultivated 
on Stalmite; macroscopic and microscopic identification 
from raw material; comparison of the protein profile with 
an in-house reference by isoelectric focusing and sodium 
dodecyl sulfate polyacrylamide gel electrophoresis; measure-
ment of the allergen activity in comparison with the in-house 
reference by enzyme-linked immunosorbent assay inhibition; 
dosage of the major allergens, ie, the allergens recognized 
by more than 50% of patients allergic to the house dust 
mite;26 extraction in optimized conditions according to Good 
Manufacture Practice; clarifying filtration with elimination 
of extractive salts and low molecular weight substances; final 
adjustment of dosage of the allergen activity in comparison 
with the in-house reference; and measurement of the biologi-
cal potency of the extract using the index of reactivity (IR).
The IR is a biological unit, and a concentration of 100 IR 
is defined by the capacity of the allergen to elicit by skin 
prick test a geometric mean wheal size of 7 mm diameter 
in 30 patients sensitive to the corresponding allergen. For 
the house dust mite, 100 IR corresponds to 40–70 µg of 
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mite proteins.25 During the standardization procedure, the 
material is in the liquid phase. The product must be stored 
between 2°C and 8°C. In this condition, the extract is stable 
for 12 months. At room temperature, the extract is stable 
for 3 months.
Practical administration
Administration regimens
Staloral 300 contains equal proportions of D. pteronyssinus 
and D. farinae and is available as a minipump-predosed 
actuator. Similar to other allergen extracts, sublingual immu-
notherapy traditionally involves an uptitration phase followed 
by maintenance treatment at the maximal dose. The recom-
mended doses during the buildup phase, with a daily dosing 
interval, are 1-2-4-8-10-30-60-120-240 IR. The 120 IR or 
240 IR dose, depending on individual tolerability, is then 
used for maintenance treatment 3–7 times a week. Rush and 
ultrarush inductions have also been proposed for routine use, 
based on the favorable safety profile of Staloral, including for 
children under the age of 5 years.27 Ultrarush schemes with 
a buildup shorter than 2 hours have been reported in adults28 
and children,29,30 with satisfactory results. In the study in 
adults, the buildup ultrarush phase involved administration 
every 5 minutes of increasing doses, reaching a cumulative 
allergen extract solution after 30 minutes that was several 
times the dose administered at the start of subcutaneous 
immunotherapy (range 4.7–525 µg of major allergens); all 
patients tolerated the treatment well.28 In the study in children, 
the ultrarush buildup phase involved administration every 
10 minutes of increasing doses of the highest concentration 
vial of sublingual immunotherapy, with mild side effects 
(mainly oral symptoms) in 19% of patients.29
The allergen extract is usually taken in the morning before 
breakfast, is kept under the tongue for a few minutes, and 
then swallowed. The term sublingual immunotherapy, unless 
otherwise stated, indicates the sublingual swallow modality. 
The maintenance dose is generally the same for all patients, 
based on the fact that, unlike subcutaneous immunotherapy, 
administration of very large amounts of allergens by the 
sublingual route does not provoke severe side effects.31 In 
one study, maintenance treatment based on a continuous or 
intermittent schedule, ie, with alternate periods of 2-month 
treatment and 2-month interruption, was equally safe.32
Criteria for starting and stopping  
treatment
Due to the perennial nature of exposure to dust mites, Staloral 
300 (Stallergenes, Antony, France) can be started at any 
period of the year. The duration of the treatment must be at 
least 3 years, as suggested in the position paper on sublingual 
immunotherapy from the World Allergy Organization in 
2009.33 This duration is usually sufficient in most patients, 
but if the clinical symptoms of allergy are not adequately 
controlled, it is possible to prolong sublingual immunotherapy 
for up to 5 years. To continue treatment beyond this time is 
unwarranted.
Clinical efficacy
There has been a number of double-blind, placebo-controlled 
studies on the efficacy of sublingual immunotherapy using 
dust mite extract in patients with mite-induced allergic rhini-
tis and allergic asthma. In 2009, Compalati et al performed a 
meta-analysis according to the Cochrane recommendations, 
as described by Jorgensen et al.34 Globally, 12 studies fulfilled 
the selection criteria, eight evaluating allergic rhinitis and nine 
evaluating allergic asthma (some studies investigated both 
diseases). The eight studies of allergic rhinitis included 194 
actively treated patients and 188 patients receiving placebo, 
and a significant reduction of symptoms (P = 0.02) and 
rescue medications (P = 0.04) was found. The nine studies 
of allergic asthma included 243 actively treated patients and 
209 patients receiving placebo, and a significant reduction of 
symptoms (P = 0.02) and rescue medications (P = 0.02) was 
found. The authors concluded that there was promising evi-
dence of efficacy for sublingual immunotherapy using mite 
extract, but suggested a need for more data from large, high-
quality, population-based studies.35 Of note, of the 12 studies 
included in the meta-analysis, six36–41 used Staloral mite, and 
five used Staloral 300.36,37,39–41 The main characteristics of 
Staloral 300 are reported in Table 1. A placebo-controlled 
study is also available addressing the efficacy of Staloral 
300 in mite-induced perennial conjunctivitis. In a group of 
45 allergic patients, 26 actively treated patients showed a 
significant increase (P , 0.04) in the allergen dose giving   
Table 1 Main characteristics of Staloral 300
Culture medium Stalmite APF®
Biological standardization Index of reactivity
Der p 1 major allergen content 60 µg/300 IR
Der p 2 major allergen content 12 µg/300 IR
Der f 1 major allergen content 150 µg/300 IR
EBM recommendation based on randomized,  
placebo-controlled trials
Asthma: A
Rhinitis: A
Conjunctivitis: A
Abbreviations: APF, animal protein-free; EBM, evidence-based medicine; IR, index 
of reactivity.
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a positive conjunctival provocation test compared with 19 
placebo-treated patients.42
Recent papers have evaluated the efficacy of Staloral 
300 in real-life settings. In a group of 39 children with 
mite-induced rhinitis and asthma not controlled by mite 
avoidance measures, sublingual immunotherapy was able 
to reduce the mean number of asthma attacks per year from 
8.2 ± 3.05 before treatment to 0.44 ± 0.79 after 3 years, ie, 
the recommended duration of sublingual immunotherapy; 
complete clinical remission was recorded in 95% of patients 
with asthma and in 82% of patients with rhinitis.43 In another 
study, 78 children with mite-induced rhinitis were evaluated 
before initiation of sublingual immunotherapy and after 6, 
12, 24, 36, and 48 months of treatment. Patient evaluation of 
allergy severity using a visual analog scale revealed signifi-
cant improvement (P , 0.001) after 6 months of treatment, 
which was maintained throughout the study period. The use of 
medications was also significantly reduced (P , 0.001) after 
6 months and remained low until the end of the study.30
Safety and tolerability
The most common side effect of sublingual immunotherapy 
is the local reaction in the mouth, that is comparable with 
the local reaction at the site of injection of subcutaneous 
immunotherapy. The systematic revisions on global aspects 
of sublingual immunotherapy44 as well as on its safety31 did 
not identify any anaphylactic reactions in the trials regardless 
of the allergen extract used. A case of anaphylaxis to Staloral 
was described by Blazowski concerning a girl who, after 
maintenance treatment with a 10-drop dose of the extract, 
following an interruption of 3 weeks, ingested 60 drops of 
the extract and developed generalized urticaria, dyspnea, and 
hypotension.45 This report highlights that even when using a 
safe method of administration such as the sublingual route, 
very high doses of allergen extracts are able to elicit severe 
systemic reactions. As far as local reactions are concerned, 
such as oral itching and burning or gastrointestinal symptoms 
once the extract is swallowed, proper management based on 
dose adjustment allows a maintenance dose to be reached.46 
It is of interest that in the systematic revision on safety of 
sublingual immunotherapy, no relationship between dose and 
systemic reactions was found, whereas local reactions were 
more frequent during treatment with low-dose extracts.31
Cost-effectiveness
The potential of allergen immunotherapy to reduce health 
care expenditure in patients with respiratory allergy can 
be understood by considering the reduction in drug use 
reported in consensus documents and meta-analyses.33,35 
Moreover, immunotherapy extends its clinical efficacy 
beyond the period of administration, because its mecha-
nism of action modifies the natural history of the allergy, 
and thus amplifies the savings in medical resources. The 
economic advantages of allergen immunotherapy over drug 
therapy for respiratory allergy, as evaluated in specifically 
designed studies, was first reported in 199547 and the avail-
able literature was recently reviewed by Berto et al.48 This 
review showed that the economic studies of allergic rhinitis 
and asthma focus on three main areas, ie, studies aimed at 
determining the cost of illness and studies focused either 
on a simple cost comparison amongst available therapeutic 
alternatives or directly comparing alternatives using full eco-
nomic evaluation, such as cost-effectiveness and cost utility 
measures. These studies have shown that immunotherapy 
may be very beneficial to health care systems, because it 
can achieve a satisfactory clinical outcome at a reduced cost 
versus standard therapy alone, and may accrue extra benefit 
at an acceptable additional cost. This is also acceptable from 
a societal perspective, ie, when indirect costs of lost produc-
tivity are considered and included in the economic analysis. 
A study using Staloral 300 is available among the published 
studies on cost-effectiveness of immunotherapy.49 This study 
included 70 patients with mite-induced asthma, comprising 
50 treated with sublingual immunotherapy in addition to 
drugs as needed and 20 treated with drugs alone. The patients 
were evaluated during a 3-year course of sublingual immuno-
therapy and for 2 further years after stopping treatment. The 
patients treated with sublingual immunotherapy in addition to 
drug therapy had a higher mean annual cost compared with 
patients treated with drug therapy alone only in the first year 
of treatment; there was no difference at year 2, the cost was 
lower (but not significantly so) at year 3 for patients treated 
with sublingual immunotherapy, and, at years 4 and 5, the 
cost became significantly lower after stopping sublingual 
immunotherapy. The total cost at year 5 was 3881 Euros for 
patients treated with sublingual immunotherapy in addition 
to drugs compared with 5020 Euros for those treated with 
drugs alone, representing a mean saving of 23%. Savings 
increased with disease severity, reaching 34% in patients 
with severe asthma.
Conclusion
The dust mite extract, Staloral 300, has good evidence for 
clinical efficacy, safety, and cost-effectiveness in patients 
with mite-induced respiratory allergy. The double-blind, 
placebo controlled trials performed using this product 
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have provided a considerable part of the scientific evidence 
obtained in a meta-analysis of the efficacy of allergen immu-
notherapy in mite-induced rhinitis and asthma.35 The safety 
of Staloral 300 relies upon the quality of the procedures 
used in its preparation, particularly the culture medium 
used for production of the extract, as well as the known low 
risk of adverse reactions with the sublingual route. Another 
advantage of sublingual immunotherapy over subcutaneous 
immunotherapy is patient compliance, given that compliance 
with the latter is limited by the inconvenience of frequent 
injections.50 Finally, the cost-effectiveness, showing a 
cost-saving capacity of immunotherapy in general and of 
sublingual immunotherapy in particular,48 is an essential 
consideration when allocating treatment for optimal man-
agement of mite-allergic patients. Allergen immunotherapy 
is the only treatment presently aimed at targeting the cause 
and not just the symptoms of respiratory allergy, but the 
quality of the materials to be used is crucial in achieving 
such an outcome.
Expert opinion
The treatments available for respiratory allergy include 
allergen avoidance, drug therapy, and allergen immu-
notherapy, but only allergen immunotherapy is able to 
address the cause and not just the symptoms of allergy. 
Allergen immunotherapy is the practice of administering 
gradually increasing doses of a specific causative allergen 
to reduce the clinical reactivity of allergic subjects. It 
was introduced a century ago51 but remained an empirical 
treatment until 1954, when the first controlled trial52 was 
performed, paving the way for a scientific approach to the 
treatment of allergy. Today, allergen immunotherapy may 
be administered in two forms, ie, subcutaneous immuno-
therapy and sublingual immunotherapy. A large number 
of trials, globally analyzed in several meta-analyses,35,53–56 
have evaluated the efficacy and safety of subcutaneous 
immunotherapy and sublingual immunotherapy in patients 
with allergic rhinitis and asthma. The available data pro-
vide solid evidence of clinical efficacy for both routes of 
administration. The mechanism of action of allergen immu-
notherapy involves modification, via allergen capture and 
presentation by Langerhans-type antigen-presenting cells, 
of the phenotype of T cells, which in allergic subjects is 
characterized by a prevalence of the Th2 type. The changes 
induced result in a Th1-type response (immune deviation) 
related to increased production of interferon-γ and IL-2 or 
to reduced Th2 activity, through a mechanism known as 
anergy or tolerance. It is now known that T cell tolerance is 
characterized by generation of allergen-specific regulatory 
T cells producing cytokines such as IL-10 and transform-
ing growth factor-beta, which have immunosuppressant 
and/or immunoregulatory activity. These mechanisms are 
similar in subcutaneous immunotherapy57,58 and sublingual 
immunotherapy.59
The house dust mite is the major cause of respiratory 
allergy worldwide, and allergen immunotherapy is an 
important part of the strategy to control this mite-induced 
disease.60 The efficacy of subcutaneous immunotherapy in 
mite-induced asthma has been clearly demonstrated,53,56 
but possible systemic reactions to injection of the allergen 
extract is a drawback. A risk factor for systemic reactions 
is the presence of asthma when the extract is administered, 
and this is particularly frequent in patients with mite allergy 
who are continuously exposed to a specific allergen. Reports 
in the 1980s of fatal anaphylactic reactions to subcutane-
ous immunotherapy61,62 highlighted this important issue, 
and have led to decreased use of this form of immuno-
therapy, especially after sublingual immunotherapy was 
introduced. In the conclusion of the latest meta-analysis 
by Abramson et al on subcutaneous immunotherapy in 
asthma, it was stated that the possibility of local or systemic 
adverse effects (such as anaphylaxis) must be considered in 
any patient.56 Sublingual immunotherapy, and particularly 
Staloral 300, has shown a reassuring safety profile. Only one 
anaphylactic reaction has been reported as a consequence of 
erroneous ingestion of a huge dose of the allergen extract,45 
and the usual safety and tolerability profile of sublingual 
immunotherapy enables administration of the high doses 
needed for clinical efficacy, immunological changes,63 and 
long-term disease-modifying effects.
Disclosure
Franco Frati, Simona Seta, Guglielmo Padua, Eleonora 
Cattaneo, Ilaria Dell’Albani, and Paola Puccinelli are 
employees of Stallergenes Italy. Marie David and Silvia 
Scurati are employees of Stallergenes France. Cristoforo 
Incorvaia is a scientific consultant of Stallergenes Italy. 
References
1.  Platts-Mills TAE, De Weck AL. Dust mite allergens and asthma – a 
worldwide problem. J Allergy Clin Immunol. 1989;83:416–427.
2.  Arlian LG, Morgan MS, Neal JS. Dust mite allergens: ecology and 
distribution. Curr Allergy Asthma Rep. 2002;2:401–411.
3.  Zock JP, Heinrich J, Jarvis D, et al. Distribution and determinants 
of house dust mite allergens in Europe: the European Community 
Respiratory Health Survey II. J Allergy Clin Immunol. 2006;118: 
682–690.
4.  Colloff MJ. Taxonomy and identification of dust mites. Allergy. 1998; 
53 Suppl 48:7–12.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
121
House dust mite extract for immunotherapyDrug Design, Development and Therapy 2012:6
  5.  Thomas WR, Hales BJ, Smith WA. House dust mite allergens in asthma 
and allergy. Trends Mol Med. 2010;16:321–328.
  6.  O’Neil SE, Heinrich TK, Hales BJ, et al. The chitinase allergens Der 
p 15 and Der p 18 from Dermatophagoides pteronyssinus. Clin Exp 
Allergy. 2006;36:831–839.
  7.  Thomas WR, Heinrich TK, Smith WA, Hales BJ. Pyroglyphid house 
dust mite allergens. Protein Pept Lett. 2007;14:943–953.
  8.  Park GM, Lee SM, Lee IY, et al. Localization of a major allergen, Der 
p 2, in the gut and faecal pellets of Dermatophagoides pteronyssinus. 
Clin Exp Allergy. 2000;30:1293–1297.
  9.  Pittner G, Vrtala S, Thomas WR, et al. Component-resolved diagnosis 
of house dust mite allergy with purified natural and recombinant mite 
allergens. Clin Exp Allergy. 2004;34:597–603.
  10.  Reese G, Ayuso R, Lehrer SB. Tropomyosin: an invertebrate 
pan-allergen. Int Arch Allergy Immunol. 1999;119:247–258.
  11.  Hales BJ, Martin AC, Pearce LJ, et al. IgE and IgG anti-house 
dust mite specificities in allergic disease. J Allergy Clin Immunol. 
2006;118:361–367.
  12.  Kidon MI, Chin CW, Kang LW, et al. Mite component-specific IgE 
repertoire and phenotypes of allergic disease in childhood: the tropical 
perspective. Pediatr Allergy Immunol. 2011;22:202–210.
  13.  Karp CL. Guilt by intimate association: what makes an allergen an 
allergen? J Allergy Clin Immunol. 2010;125:955–960.
  14.  Jacquet A. The role of house dust mites-induced innate immunity 
in development of allergic response. Int Arch Allergy Immunol. 
2011;155:95–105.
  15.  Bessot JC, Pauli G. Mite allergens: an overview. Eur Ann Allergy Clin 
Immunol. 2011;43:141–156.
  16.  Jacquet A. The role of innate immunity activation in house dust mite 
allergy. Trends Mol Med. 2011;17:604–611.
  17.  Novak N, Koch S, Allam JP, Bieber T. Dendritic cells: bridging innate 
and adaptive immunity in atopic dermatitis. J Allergy Clin Immunol. 
2010;125:50–59.
  18.  Inal A, Kendirli SG, Yilmaz M, et al. Indices of lower airway inflamma-
tion in children monosensitized to house dust mite after nasal allergen 
challenge. Allergy. 2008;63:1345–1351.
  19.  Incorvaia C, Frati F, Verna N, D’Alò S, Motolese A, Pucci S. Allergy 
and the skin. Clin Exp Immunol. 2008;153 Suppl 1:27–29.
  20.  Leung DYM. Our evolving understanding of the functional role of 
filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2009;124: 
494–495.
  21.  Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled 
corticosteroids in preschool children at high risk of asthma. N Engl 
J Med. 2006;354:1985–1997.
  22.  Simpson A, Custovic A. The role of allergen avoidance in the secondary 
prevention of atopic disorders. Curr Opin Allergy Clin Immunol. 
2005;5:223–227.
  23.  Incorvaia C, Frati F. One century of allergen-specific immunotherapy 
for respiratory allergy. Immunotherapy. 2011;3:629–635.
  24.  Dreborg S. Mite allergens: collection, determination, expression of 
results and risk levels for sensitization and symptoms induction. Allergy. 
1998;53 Suppl 48:88–91.
  25.  Batard T, Hrabina A, Bi XZ, et al. Production and proteomic charac-
terization of pharmaceutical-grade Dermatophagoides pteronyssinus 
and Dermatophagoides farinae extracts for allergy vaccines. Int Arch 
Allergy Immunol. 2006;140:295–305.
  26.  van Ree R. Indoor allergens: relevance of major allergen measurements 
and standardization. J Allergy Clin Immunol. 2007;119:270–277.
  27.  Fiocchi A, Pajno G, La Grutta S, et al. Safety of SLIT in children aged 
3 to 7 years. Ann Allergy Asthma Immunol. 2005;95:254–258.
  28.  Rossi R, Monasterolo RE. A pilot study of feasibility of ultra-rush 
(20–25 minutes) sublingual-swallow immunotherapy in 679 patients 
(699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol 
Pharmacol. 2005;18:277–285.
  29.  Tripodi S, Di Rienzo Businco A, Benincori N, et al. Safety and toler-
ability of ultra-rush induction, less than one hour, of sublingual immu-
notherapy in children. Int Arch Allergy Immunol. 2005;139:149–152.
  30.  Ferres J, Justicia JR, Garcia MP, et al. Efficacy of high-dose sublingual 
immunotherapy in children allergic to house dust mites in real-life 
clinical practice. Allergol Immunopathol (Madr). 2011;39:122–127.
  31.  Gidaro GB, Marcucci F, Sensi L, et al. The safety of sublingual-swallow 
immunotherapy: an analysis of published studies. Clin Exp Allergy. 
2005;35:565–571.
  32.  Cadario G, Ciprandi G, Di Cara G, et al. Comparison between continu-
ous or intermittent schedules of sublingual immunotherapy for house 
dust mites: effects on compliance, patient’s safisfaction, quality of life, 
and safety. Int J Immunopathol Pharmacol. 2008;21:471–473.
  33.  Canonica GW, Bousquet J, Casale T, et al. Sublingual immunotherapy: 
World Allergy Organization Position Paper 2009. Allergy. 2009; 
64 Suppl 91:1–59.
  34.  Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared 
with industry supported meta-analyses and other meta-analyses of the 
same drugs: systematic review. Br Med J. 2006;333:782.
  35.  Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy 
of sublingual immunotherapy for house dust mites respiratory allergy: 
results of a GA2LEN meta-analysis. Allergy. 2009;64:1570–1579.
  36.  Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual swallow 
immunotherapy (SLIT) in patients with asthma due to house dust mites: 
a double-blind placebo-controlled study. Allergy. 1999;54:249–260.
  37.  Guez S, Vatrinet C, Fadel R, Andrè C. House dust mite sublingual 
swallow immunotherapy in perennial rhinitis: a double-blind placebo-
controlled study. Allergy. 2000;55:369–375.
  38.  Bahcecilier NN, Isik U, Barlan IB, Basaran N. Efficacy of sublingual 
immunotherapy in children with asthma and rhinitis: a double-blind, 
placebo-controlled trial. Pediatr Pulmonol. 2001;32:49–55.
  39.  Niu CK, Chen WY, Huang JL, et al. Efficacy of sublingual 
immunotherapy with high-dose mite extracts in asthma: a multi-center, 
double-blind, randomized, and placebo-controlled study in Taiwan. 
Respir Med. 2006;100:1374–1383.
  40.  Lue KH, Lin YH, Sun HL, et al. Clinical and immunological effect of 
sublingual immunotherapy in asthmatic children sensitized to mites: 
 a double-blind, randomized, placebo-controlled study. Pediatr Allergy 
Immunol. 2006;17:408–415.
  41.  Pham-Ti N, Scheinmann P, Fadel R, et al. Assessment of sublingual 
immunotherapy efficacy in children with house dust mite-induced 
allergic asthma optimally controlled by pharmacologic treatment and 
mite-avoidance measures. Pediatr Allergy Immunol. 2007;18:47–57.
  42.  Mortemousque B, Bertel F, De Casamayor P, et al. House-dust mite 
sublingual-swallow immunotherapy in perennial conjunctivitis: 
a double-blind, placebo-controlled study. Clin Exp Allergy. 
2003:33464–33469.
  43.  Nuhoglu Y, Ozumut SS, Ozdemir C, et al. Sublingual immunotherapy to 
house dust mites in pediatric patients with allergic rhinitis and asthma:   
a retrospective analysis of clinical course over a 3-year follow-up period. 
J Investig Allergol Clin Immunol. 2007;17:375–378.
  44.  Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews 
of sublingual immunotherapy (SLIT). Allergy. 2011;66:740–752.
  45.  Blazowski L. Anaphylactic shock because of sublingual immuno-
therapy overdose during third year of maintenance dose. Allergy. 
2008;63:374.
  46.  Frati F, Sensi L, Di Rienzo V , et al. A model for management of sublin-
gual immunotherapy. Eur Ann Allergy Clin Immunol. 2003;35:56–60.
  47.  Buchner K, Siepe M. Nutzen der Hyposensibilisierung unter 
wirtschaftlichen Aspekten. [Benefits of immunotherapy with economic 
aspects]. Allergo J. 1995;4:156–163. German.
  48.  Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy:   
a review. Curr Opin Allergy Clin Immunol. 2008;8:585–589.
  49.  Ariano R, Berto P, Incorvaia C, et al. Economic evaluation of sublin-
gual immunotherapy vs symptomatic treatment in allergic asthma. Ann 
Allergy Asthma Immunol. 2009;103:254–259.
  50.  Incorvaia C, Mauro M, Ridolo E, et al. Patient’s compliance with 
allergen immunotherapy. Patient Prefer Adherence. 2008;2:247–261.
  51.  Noon L, Cantab BC, Eng FR. Prophylactic inoculation against hay 
fever. Lancet. 1911;177:1572–1573.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
122
Frati et alDrug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2012:6
  52.  Frankland A, Augustin R. Prophylaxis of summer hay fever and asthma: 
a controlled trial comparing crude grass pollen extract with the isolated 
main protein components. Lancet. 1954;266:1055–1058.
  53.  Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective 
in asthma? A meta-analysis of randomized controlled trials. Am J Respir 
Crit Care Med. 1995;151:969–974.
  54.  Calderon MA, Alves B, Jacobson M, et al. Allergen injection immu-
notherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 
2007;1:CD001936.
  55.  Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual 
immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 
2010;12:CD002893.
  56.  Abramson MJ, Puy RM, Weiner JM. Injection immunotherapy for 
asthma. Cochrane Database Syst Rev. 2010;8:CD001186.
  57.  Maggi E. T cell responses induced by allergen-specific immunotherapy. 
Clin Exp Immunol. 2010;161:10–18.
  58.  Taylor A, Verhagen J, Blaser K, et al. Mechanisms of immune 
suppression by interleukin-10 and transforming growth factor beta: 
the role of T regulatory cells. Immunology. 2006;117:433–442.
  59.  Bohle B, Kinaciyan T, Gestrmayr M, et al. Sublingual immuno-
therapy induces IL-10-producing T regulatory cells, allergen-specific 
T. cell tolerance, and immune deviation. J Allergy Clin Immunol. 
2007;120:707–713.
  60.  Gaffin JM, Phipatanakul W. The role of indoor allergens in the develop-
ment of asthma. Curr Opin Allergy Clin Immunol. 2009;9:128–135.
  61.  Committee on Safety in Medicine. CSM update: desensitizing vaccines. 
Br Med J. 1986;293:948.
  62.  Lockey RF, Benedikt LM, Turkeltaub PC, Bukantz SC. Fatalities from 
immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 
1987;79:660–677.
  63.  Marcucci F, Sensi L, Di Cara G, et al. Dose dependence of immunological 
response to sublingual immunotherapy. Allergy. 2005;60:952–956.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
123
House dust mite extract for immunotherapy